CompletedPhase 1NCT00575952
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
Studying Squamous cell carcinoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Group
- Principal Investigator
- D. McMeekinNRG Oncology
- Intervention
- Cisplatin(drug)
- Enrollment
- 27 enrolled
- Eligibility
- FEMALE
- Timeline
- 2008 – 2016
Study locations (9)
- Hartford Hospital, Hartford, Connecticut, United States
- The Hospital of Central Connecticut, New Britain, Connecticut, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Cooper Hospital University Medical Center, Camden, New Jersey, United States
- Case Western Reserve University, Cleveland, Ohio, United States
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- Women and Infants Hospital, Providence, Rhode Island, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00575952 on ClinicalTrials.gov